GlassScriptPhysician profile
Michael Bernard Boyle
NPI 1558051854
$914.98
in general payments reported to CMS, 2019-2025
13 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $296 · 2024: $358 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $158.64 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.72 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $140.49 | 2025 | Eluvia |
| Emd Serono, INC. | $125.00 | 2023 | |
| Philips North America LLC | $98.61 | 2024 | (5044) Mcot |
| Cook Medical LLC | $67.45 | 2024-2025 | Cook Celect, Lunderquist, Zenith |
| Solventum Corporation | $40.25 | 2024 | Activ.A.C. |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2023 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $22.24 | 2023 | Opsumit |
| Otsuka America Pharmaceutical, INC. | $21.53 | 2023 | Jynarque |
| Glaxosmithkline, LLC. | $19.32 | 2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $17.41 | 2023 | |
| Genzyme Corporation | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.